Two of these, ICAM1 and ATM, are existing drug targets used in the treatment of multiple sclerosis, fatigue, orthostatic hypotension and osteoarthritis (natalizumab, caffeine and hyaluronic acid, respectively) and may provide potential targets for repositioning. This evidence concerns the gene ICAM1 and multiple sclerosis.